arb

5 interactions related to arb

losartan + potassium

Losartan blocks the angiotensin II receptor, lowering aldosterone and reducing renal potassium excretion in the same way ACE inhibitors do. Concurrent potassium supplementation can drive serum potassium into the hyperkalemic range, with cardiac arrhythmia risk in patients with kidney impairment, diabetes, or heart failure.

high
losartanpotassiumarbhyperkalemiablood pressureraaskidneysupplement interaction

losartan + licorice

Glycyrrhizin in licorice mimics aldosterone, causing renal sodium and water retention and potassium loss. This pseudoaldosteronism raises blood pressure and counteracts losartan's antihypertensive effect, while also producing hypokalemia that can cause weakness and arrhythmia.

high
losartanlicoriceglycyrrhizinarbblood pressurehypertensionpseudoaldosteronismherb interaction

losartan + hawthorn

Hawthorn produces modest blood pressure lowering (roughly 5 to 11 mmHg systolic in clinical trials) through vasodilation and mild ACE-like activity. Combined with losartan, the additive effect could occasionally cause hypotension or dizziness, particularly in people on multiple antihypertensives or those starting hawthorn at high doses.

low
losartanhawthornarbblood pressurehypotensionherb interactioncrataeguscardiovascular

valsartan + spirulina

Spirulina has modest antihypertensive effects in clinical trials (systolic drop of around 4-5 mmHg) and contains roughly 14 mg of potassium per gram. Combined with valsartan, theoretical risks include additive blood pressure lowering and a minor contribution to potassium load, though at typical supplement doses neither effect is large.

low
valsartanspirulinaarbblood pressurehypertensionpotassiumsupplement interactiondiovan

valsartan + potassium

Valsartan is an angiotensin II receptor blocker that suppresses aldosterone and slows renal potassium excretion. The FDA-approved Diovan label specifically warns that potassium supplements and potassium-containing salt substitutes may lead to clinically significant hyperkalemia, particularly in patients with renal impairment, diabetes, or heart failure.

high
valsartanpotassiumarbhyperkalemiablood pressurediovanraasfda label